Kabi Is Ready To Get More Aggressive On US Market Share

 
• By Aidan Fry

With supply shortages easing and a period of channel destocking largely over, Fresenius Kabi’s US injectables business is preparing to fight hard to maintain its market position, group CEO Stephan Sturm says.

Chocolate_Cake
Fresenius Kabi is ready to act aggressively to defend its share of the US intravenous generics market • Source: Shutterstock

More from Drug Pricing

More from Policy & Regulation